Co-Authors
This is a "connection" page, showing publications co-authored by ANDREW FUTREAL and KOICHI TAKAHASHI.
Connection Strength
1.266
-
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022 10 20; 140(16):1753-1763.
Score: 0.225
-
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.
Score: 0.223
-
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
Score: 0.210
-
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
Score: 0.143
-
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res. 2023 05 15; 29(10):1938-1951.
Score: 0.059
-
Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. EJHaem. 2020 Nov; 1(2):552-557.
Score: 0.049
-
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 10; 187(1):e1-e4.
Score: 0.045
-
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
Score: 0.044
-
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
Score: 0.043
-
Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 01 01; 37(1):7-11.
Score: 0.043
-
MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
Score: 0.041
-
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
Score: 0.040
-
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.
Score: 0.036
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
Score: 0.034
-
Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013 Oct; 14(10):703-18.
Score: 0.030